ArticleLife science alliance2025
DA-Raf synergistically binds to the plasma membrane and Ras to suppress ERK signaling.
Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The small GTPase Ras on the plasma membrane (PM) activates the ERK pathway (Raf-MEK-ERK signaling pathway) to regulate a variety of cellular, physiological, and pathological events. DA-Raf1 (DA-Raf) is a splicing isoform of A-Raf and contains the Ras-binding domain and the Cys-rich domain but lacks the conserved region 2 (CR2) and CR3 containing the kinase domain. Accordingly, DA-Raf dominant-negatively regulates Raf proteins to prevent the Ras-ERK pathway. We elucidate here the mechanisms of how DA-Raf conducts its dominant-negative function on Raf proteins. Because DA-Raf lacks the CR2 and CR3, it was incapable of adopting the autoinhibitory closed conformation and thereby favorable for PM localization. Basic amino acids in DA-Raf Ras-binding domain, and those in the Cys-rich domain, were essential for the interaction with phosphatidylserine in the PM. This interaction favored the cooperative binding of DA-Raf to active Ras, which predominated over that of Raf proteins, leading to the stable PM association of DA-Raf. Consequently, DA-Raf exerts its dominant-negative function on Raf proteins to prevent the Ras-ERK pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.